FindTrial
Sign In

FOR46

DRUG3 trials

Sponsors

Fortis Therapeutics, Inc., Rahul Aggarwal

Conditions

Metastatic Castration-resistant Prostate CancerMultiple MyelomaMultiple Myeloma With Failed RemissionMultiple Myeloma in RelapseProstate CancerProstate Cancer Metastatic

Phase 1

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CompletedNCT03575819
Fortis Therapeutics, Inc.Prostate Cancer Metastatic
Start: 2019-02-04End: 2023-11-22Updated: 2024-02-01
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
CompletedNCT03650491
Fortis Therapeutics, Inc.Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
Start: 2019-04-03End: 2022-01-31Updated: 2022-07-27
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Active, not recruitingNCT05011188
Rahul AggarwalMetastatic Castration-resistant Prostate Cancer, Prostate Cancer
Start: 2022-01-19End: 2027-07-31Updated: 2026-09-17

Related Papers

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology2025-03-266 citations
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2024-06-016 citations
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
Journal of Experimental & Clinical Cancer Research2023-03-1135 citations
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-06-0120 citations